![From fast food worker to cybersecurity engineer with Tae'lur Alexis [Podcast #169]](https://cdn.hashnode.com/res/hashnode/image/upload/v1745242807605/8a6cf71c-144f-4c91-9532-62d7c92c0f65.png?#)
Thousands of women to benefit from twice-a-day pill for most common breast cancer in what scientists describe as a 'landmark moment'
Results from a clinical trial showed that capivasertib plus the hormone therapy fulvestrant increased the time before the cancer got worse by around 4.2 months compared with placebo plus fulvestrant.
Results from a clinical trial showed that capivasertib plus the hormone therapy fulvestrant increased the time before the cancer got worse by around 4.2 months compared with placebo plus fulvestrant.
